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Abstract
Summary The aim of this study was to determine the efficacy
of once-weekly teriparatide as a function of baseline fracture
risk. Treatment with once-weekly teriparatide was associated
with a statistically significant 79 % decrease in vertebral frac-
tures, and in the cohort as a whole, efficacy was not related to
baseline fracture risk.
Introduction Previous studies have suggested that the efficacy
of some interventions may be greater in the segment of the
population at highest fracture risk as assessed by the FRAX®
algorithms. The aim of the present study was to determine
whether the antifracture efficacy of weekly teriparatide was
dependent on the magnitude of fracture risk.
Methods Baseline fracture probabilities (using FRAX) were
computed from the primary data of a phase 3 study (TOWER)
of the effects of weekly teriparatide in 542 men and postmen-
opausal women with osteoporosis. The outcome variable
comprised morphometric vertebral fractures. Interactions
between fracture probability and efficacy were explored by
Poisson regression.
Results The 10-year probability of major osteoporotic frac-
tures (without BMD) ranged from 7.2 to 42.2 %. FRAX-
based hip fracture probabilities ranged from 0.9 to 29.3 %.
Treatment with teriparatide was associated with a 79 %
(95 % CI 52–91 %) decrease in vertebral fractures assessed
by semiquantitative morphometry. Relative risk reductions for
the effect of teriparatide on the fracture outcome did not
change significantly across the range of fracture probabilities
(p=0.28). In a subgroup analysis of 346 (64 %) participants
who had FRAX probabilities calculated with the inclusion of
BMD, there was a small but significant interaction (p=0.028)
between efficacy and baseline fracture probability such that
high fracture probabilities were associated with lower
efficacy.
Conclusion Weekly teriparatide significantly decreased the
risk of morphometric vertebral fractures in men and postmen-
opausal women with osteoporosis. Overall, the efficacy of
teriparatide was not dependent on the level of fracture risk
assessed by FRAX in the cohort as a whole.
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Introduction
The continuous endogenous production of excess parathyroid
hormone (PTH), as seen in primary or secondary hyperpara-
thyroidism, or its exogenous administration, may give rise to
deleterious consequences for the skeleton, particularly in cor-
tical bone. However, intermittent administration of PTH (e.g.,
with daily or weekly subcutaneous injections) results in an
increase of the number and activity of osteoblasts, leading to
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an increase in bone mass and in an improvement in skeletal
architecture at both cancellous and cortical skeletal sites [1–3].
The intact molecule (amino acids 1–84) and the 1–34 N-ter-
minal fragment (teriparatide) are used in the management of
osteoporosis [4]. Treatment with either agent has been shown
to reduce significantly the risk of vertebral fractures, whereas
teriparatide has also been shown to have an effect on
nonvertebral fractures [5–9]. Beneficial effects on
nonvertebral fracture with teriparatide have been shown to
persist for up to 30 months after stopping treatment [10].
Several studies have examined the interaction between
FRAX-based probabilities at baseline and subsequent effec-
tiveness. Three of these reanalyses of clinical trial data have
shown greater efficacy against fracture in individuals at higher
risk treated with clodronate or bazedoxifene [11–13] whereas
others have shown stable benefits of strontium ranelate or
raloxifene across a range of fracture probabilities (but with
greater absolute risk reductions in those at higher risk)
[13–15]. In a further preplanned analysis of the FREEDOM
trial, greater efficacy against fracture was shown in individuals
at higher risk treated with denosumab [16]. No data are avail-
able for teriparatide or PTH.
Against this background, the aim of the present study was
to seek interactions between teriparatide-induced effects on
fracture and baseline fracture probability determined by
FRAX® as now requested for new phase 3 studies by the
European regulatory body [17]. The hypothesis tested was
that weekly teriparatide reduced the risk of fracture irrespec-
tive of pretreatment fracture probability.
Methods
TOWER study
The Teriparatide Once-Weekly Efficacy Research (TOWER)
trial, conducted in Japan, was a randomized phase 3 double-
blind placebo-controlled study of the effects of once-weekly
teriparatide on the risk of vertebral fracture. The details have
been previously published [9]. In brief, men and postmeno-
pausal women aged between 65 and 95 years were eligible for
the study if they had one to five vertebral fractures and low
bone mineral density (BMD). Morphometric vertebral frac-
tures at baseline were identified using semiquantitative (SQ)
and quantitative assessments [18]. Prevalent vertebral fracture
at baseline was defined as a 20 % or greater reduction in the
vertebral height in any of the anterior, posterior, or central
vertebral heights, or from corresponding values in the adjacent
upper or lower vertebra. Low BMD was defined as <80 % of
the young adult mean value at the lumbar spine, femoral neck,
total hip, or distal radius measured by dual-energy X-ray ab-
sorptiometry. At the femoral neck, this corresponds to a T-
score of<−1.67 SD, using the NHANES young female
reference range [19]. In participants who did not undergo
DXA measurement, bone mass was assessed by second meta-
carpal radiogrammetry, with low BMD again defined as
<80 % young adult mean.
Participants were randomly assigned to receive weekly
subcutaneous injections of teriparatide 56.5 μg or placebo
for 72 weeks in a 1:1 ratio. All subjects received daily oral
supplements of calcium 610 mg, vitamin D 400 IU, and mag-
nesium 30 mg. The primary outcome variable was vertebral
fracture assessed from radiographs taken at 24, 48, and
72 weeks. An incident fracture was identified by an increase
of at least one SQ grade and a 20 % or greater decrease from
baseline of vertebral height in any of the anterior, posterior, or
central vertebral heights.
The study enrolled 578 men and women, and data were
available in 542 for analysis. Treatment with once-weekly
teriparatide reduced the incidence of vertebral fractures com-
pared to placebo (relative risk: 0.20; 95 % CI: 0.09–0.45;
p<0.01) [9].
Assessment of fracture probability
The 10-year probability of a major osteoporotic fracture (clin-
ical spine, forearm, humerus, or hip fracture) and of a hip
fracture was computed using the Japanese FRAX® model
(http://www.shef.ac.uk/FRAX) (version 3.8) [20, 21]. The
primary analysis used baseline 10-year probability of major
fracture. For each probability, calculations were made using
information on the clinical risk factors alone since femoral
neck BMD was available in only a subset of patients (64 %).
In an additional analysis, we also examined the 10-year prob-
ability of hip fracture as a risk variable. In a subgroup analysis,
we calculated fracture probabilities that included femoral neck
BMD.
Probability of fracture was calculated in men or women
from age, body mass index (BMI) computed from height
and weight, and dichotomized risk variables that comprised
a prior fragility fracture, parental history of hip fracture, cur-
rent tobacco smoking, ever long-term use of oral glucocorti-
coids, rheumatoid arthritis, other causes of secondary osteo-
porosis, and daily alcohol consumption of 3 or more units
daily. Information on sex, age, BMI, and previous fracture
was available in all patients. Past use of glucocorticoids, rheu-
matoid arthritis, and other secondary causes of osteoporosis
were exclusion criteria, and a Bno^ response was entered.
There was no information available for parental history of
hip fracture, current smoking, and alcohol intake, and these
variables was set to no for all subjects.
In the subgroup in which femoral neck BMD was avail-
able, BMDwas additionally entered to yield the 10-year prob-
abilities as defined above with the inclusion of BMD. BMD
was measured using equipment from two different manufac-
turers (Hologic and GE-Lunar). BMDwere standardized [22],
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and T-scores were computed from the NHANES young fe-
male reference range [19].
Statistical methods
This was an intention to treat (ITT) analysis. For the effects of
teriparatide on fracture outcomes, an extension of Poisson
regression model was used [23]. In contrast to logistic regres-
sion, the Poisson regression utilizes the length of each indi-
vidual’s follow-up period, and the hazard function is assumed
to be exp (β0+β1·time from baseline+β2·current age+β3·
current variable of interest). The observation period of each
participant was divided in intervals of 1 month. One fracture
per person was counted.
For the assessment of overall efficacy, the following regres-
sion model was used: (1) constant, (2) current time, (3) current
age, (4) treatment (teriparatide versus placebo, where 1=
teriparatide and 0=placebo).
The interaction between treatment and 10-year probability
was examined with the model: (1) constant, (2) current time,
(3) current age, (4) treatment (teriparatide versus placebo), (5)
10-year probability, (6) treatment×10-year probability.
Hazard ratios (HR) for treatment effect and 95 % confi-
dence intervals (95 % CI) were computed as a continuous
variable. For ease of presentation in tables, % relative risk
reduction (RRR=100−hazard ratio*100) is shown at the
10th, 25th, 50th, 75th, and 90th percentile of fracture proba-
bility. Two-sided p values were used for all analyses and
p<0.05 considered to be significant.
Results
A total number of 542 men and women were studied aged 65–
90 years (mean age 75.4 years, SD 5.8 years; median age
75 years, IQR 71 to 79 years) of whom 96 % were female.
BMI ranged from 15 to 37 kg/m2 (mean 23.0 kg/m2, SD
3.3 kg/m2). Forty-four patients sustained a new vertebral frac-
ture identified by vertebral morphometry.
Summary effects of treatment
Overall, once-weekly teriparatide was associated with a statis-
tically significant 79 % decrease in morphometric vertebral
fractures (HR 0.21; 95 % CI 0.09–0.48).
10-year fracture probability
For each patient, the 10-year probability of a major osteopo-
rotic fracture (clinical spine, hip, forearm, and humerus frac-
ture) was calculated using FRAX without BMD. Mean prob-
abilities are shown in Table 1, together with probabilities for
hip fracture. The 10-year probability of a major fracture
ranged from 7.2 to 42.2 %, with 3.7 % participants having a
probability ≤10 %. A similar range was observed in the subset
with BMD available to be included in the FRAX calculations,
where 2.6 % had a probability of major fracture ≤10 %.
Interaction between treatment and fracture probability
Table 2 shows the effect of teriparatide at different percentiles
of FRAX probabilities for a major osteoporotic fracture and
hip fracture calculated without BMD (n=542). The relative
risk reduction (RRR) tended to decrease with increasing frac-
ture probability, but the interaction between treatment effect
and fracture probability was not significant (p=0.28). The
relationship is shown as a continuous function in Fig. 1 and
at given percentiles of baseline probability in Table 2. Al-
though there was a suggestion that lower age was associated
with increased efficacy, the test for interaction did not achieve
statistical significance (p=0.24).
Hip fracture probability
Mean probabilities of hip fracture at baseline are shown in
Table 1. The 10-year probability of a hip fracture ranged from
0.9 to 29.3 %. As was the case for the probability of a major
Table 1 Ten-year probability of a major osteoporotic fracture (%) and
hip fracture (%) estimated at baseline with and without the inclusion of
BMD, assuming no treatment
FRAX model
Major osteoporotic fracture Hip fracture
Without BMD With BMD Without BMD With BMD
n 542 346 542 346
Mean 25.3 26.0 9.3 9.0
SD 8.5 9.6 5.7 5.8
Range 7.2–42.2 6.3–56.8 0.9–29.3 0.5–32.4
Table 2 Relative risk reduction (RRR, %) between treatments
(teriparatide versus placebo) for morphometric vertebral fractures at
different values of 10-year probability of a major osteoporotic fracture
(MOF) calculated without BMD, assuming no treatment
Percentile FRAX 10-year
probability, no treatment
RRR
Estimate 95 % CI
10th 14.7 % 90 % 45–98 %
25th 18.5 % 87 % 51–97 %
50th 24.5 % 82 % 55–93 %
75th 32.9 % 71 % 27–89 %
90th 36.6 % 64 % 0–89 %a
a 95 % CI relative risk fracture teriparatide versus placebo=0.11–1.12
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fracture, efficacy tended to decrease with increasing fracture
probability (Table 3), but the interaction between treatment
effect and fracture probability was not statistically significant
(p>0.30).
Subgroup analysis
A total of 542 men and women were studied, of whom all had
information on the clinical risk factors. Of these, 346 (64 %)
had additional information on BMD, and 196 (36 %) were
included on the basis of metacarpal radiogrammetric mea-
sures. The mean T-score for BMD at the femoral neck was
−2.8±0.7 SD and ranged from −4.7 to −0.9 SD.Mean age was
slightly lower in patients with a DXA BMD test than in those
without [74.9±5.8 years versus 76.1±5.7 (p=0.031)]. BMI
was similar in the two groups (23.0±3.2 versus 22.8±
3.5 kg/m2, respectively; p>0.30). In the subgroup in which
BMDwas measured, new vertebral fractures were noted in 27
patients. The effect of weekly teriparatide on vertebral fracture
risk was similar to that observed in the entire population (HR:
0.20; 95 % CI: 0.07–0.57).
In this subgroup with DXA BMD measured, the mean
probability of a major fracture was 26.0 %, marginally higher
than for the entire population (see Table 2). Table 4 demon-
strates the effects of teriparatide at different percentiles of
FRAX probabilities for a major osteoporotic fracture calculat-
ed with BMD. There was a statistically significant interaction
between FRAX probability and efficacy (p=0.028), such that
high major osteoporotic fracture probabilities were associated
with lower efficacy. This appeared to be driven bymuch lower
apparent efficacy in the population above the 90th centile for
baseline fracture probability. However, the 95 % CI around
the efficacy point estimate in this group spanned from a risk
increase to an RRR of 85 %. Apart from the 90 % centile, the
effect was quantitatively similar to that observed in the ab-
sence of BMD in the FRAX model. For example, the RRR
for fracture probabilities with BMD at the 25th and 75th
0.0
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0.6
0.8
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1.2
14 16 18 20 22 24 26 28 30 32 34 36
HR
10 year probability of major fracture (%)
Without BMD p=0.28
Fig. 1 Hazard ratio between
treatments (teriparatide versus
placebo) for morphometric
vertebral fractures according to
the 10-year probability of a major
osteoporotic fracture calculated
without inclusion of BMD (HR
presented from 10th to 90th
percentile). Note that greater HR
implies lower efficacy
Table 3 Relative risk reduction (RRR, %) between treatments
(teriparatide versus placebo) for morphometric vertebral fractures at
different values of 10-year probability of hip fracture calculated without
BMD, assuming no treatment
Percentile FRAX 10-year
probability,
no treatment
RRR
Estimate 95 % CI
10th 3.4 % 86 % 49–96 %
25th 4.9 % 85 % 52–95 %
50th 8.0 % 82 % 54–93 %
75th 12.1 % 77 % 49–90 %
90th 18.4 % 68 % 1–90 %
Table 4 Relative risk reduction (RRR, %) between treatments
(teriparatide versus placebo) for morphometric vertebral fractures at
different values of 10-year probability of a major osteoporotic fracture
calculated with inclusion of BMD, assuming no treatment
Percentile FRAX 10-year
probability,
no treatment
RRR
Estimate 95 % CI
10th 13.7 % 97 % 68–100 %
25th 18.8 % 95 % 63–99 %
50th 25.4 % 90 % 53–98 %
75th 31.8 % 89 % 28–94 %
90th 39.0 % 50 % 0–85 %a
a 95 % CI relative risk fracture teriparatide versus placebo=0.15–1.69
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centiles were 95 and 79 %, respectively (Table 4). The corre-
sponding RRRs at probabilities without BMD were 87 and
71 % (Table 2). When associations were examined in the
group who had undergone DXA BMD measurement, but
without inclusion of BMD in the model, the interaction term
did not achieve statistical significance (p=0.13), raising the
possibility of a BMD-efficacy interaction. This interaction
was of borderline statistical significance (p=0.055) and doc-
umented in Table 5. When the analysis was restricted to those
individuals who were included on the basis of metacarpal
radiogrammetry, there was again no evidence of an interaction
between treatment and baseline risk for fracture occurrence
(p=0.30).
Discussion
The present study demonstrated a marked effect of teriparatide
given weekly on the occurrence of new vertebral fractures,
with a relative risk reduction of 79%, consistent with previous
findings in this cohort [9], and others relating to both weekly
[6] and daily teriparatide [7]. However, in this current analy-
sis, there was no evidence of a significant interaction between
fracture probability and efficacy in the cohort as a whole.
There was a small but statistically significant interaction be-
tween efficacy and baseline fracture probability calculated
with inclusion of BMD, in the sense that marginally lower
efficacy was evident at higher fracture probabilities. This ap-
peared to be a consequence of an interaction between efficacy
and BMD, driven by the subgroup of participants in the lowest
10 % of BMD and highest 10 % baseline fracture risk.
Earlier studies of raloxifene [13, 14] and strontium ranelate
[15] yielded similar findings with respect to a lack of variation
in efficacy according to baseline fracture probability. Howev-
er, they contrast with results from reanalysis of two other
phase III studies [11, 12]. In the first of these, a marked trend
toward greater fracture reduction at higher baseline fracture
probability was observed in a 3-year prospective, randomized,
placebo-controlled trial of oral clodronate in elderly women,
identified from general practice registers. When BMD was
excluded from the calculation of probability, the interaction
was statistically significant [11], and there was some evidence
of a threshold with efficacy apparent at fracture probabilities
exceeding 20 %. These data are complemented by findings of
a significant effect of bazedoxifene on clinical fractures with
fracture probabilities that exceeded 17 % [12]. More recently,
evidence of a similar interaction between efficacy and baseline
fracture probability has been reported for denosumab [16].
In the current analysis, there was evidence, albeit not
achieving statistical significance, of greater efficacy among
younger participants, consistent with other recent findings
[24]. Indeed, we also found, in the subgroup in whom DXA
BMD measures were included in the FRAX calculation, that
efficacy appeared lower in those with lowest BMD (and who
tended to be older). Interestingly, the treatment-induced in-
crease in lumbar spine BMD in this trial somewhat lower than
that in the pivotal study of the daily medication (6.4 versus
9.7 %) [7]. However, given that our analysis was within one
trial and the constraints of a non-head-to-head comparison and
different study populations, this is unlikely to explain our
results. As the efficacy-BMD interaction was driven primarily
by those individuals in the top 10% of fracture probability and
lowest 10 % of BMD, with efficacy in the remainder of the
population similar across the distribution and in those with or
without BMD measures, we view this observation as of inter-
est but requiring confirmation. Additionally, the definition of
incident vertebral fracture differed between the TOWER trial
and the pivotal trial of daily teriparatide. Although a similar
SQ approach was employed in both trials, in the latter study,
new fractures were only considered in previously normal ver-
tebrae, and analyses conducted separately for all and
moderate/severe fractures; in the TOWER trial, worsening of
pre-existing fractures was considered if the change was by at
least one SQ grade and by >20 %. These different approaches
may lead to variation in the magnitude of treatment effect
demonstrated, but as they are consistent between treatment
and placebo groups within each study, there is no reason to
suppose that they would influence interactions between base-
line risk and treatment [25].
Patients included in the TOWER trial of weekly
teriparatide had relatively high pre-treatment fracture risks.
Indeed, only 3.6% had a baseline probability of major fracture
≤10%. It is possible, therefore, that any attenuation of efficacy
with low fracture probabilities might be seen in patients at
much lower risk than those recruited to TOWER. In the present
analysis, the mean 10-year probability of a major fracture cal-
culated using FRAX including BMD was 26 %. This com-
pares with 21 % in the raloxifene study [14], in which no
fracture probability-efficacy interaction was documented, but
contrasts with the lower value of 10.9 % in the analysis of
bazedoxifene [12], in which an interaction between antifracture
Table 5 Relative risk reduction (RRR, %) between treatments
(teriparatide versus placebo) for morphometric vertebral fractures at
different T-score values of BMD
Percentile BMD RRR
Estimate 95 % CI
10th −3.7 49 % 0–86 %a
25th −3.3 73 % 17–81 %
50th −2.8 88 % 50–97 %
75th −2.4 94 % 57–99 %
90th −2.0 97 % 61–100 %
a 95 % CI relative risk fracture teriparatide versus placebo=0.14–1.81
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efficacy and baseline fracture probability was observed. How-
ever, in the clodronate study [11], where an interaction was
found, the mean probability was 18 %, although the overall
range of probabilities was greater. Further analyses of phase 3
studies with a mean baseline fracture probability toward the
lower part of the overall distribution may help to clarify such
findings.
There are a number of limitations to this study that should
be considered in the interpretation of the results. First, the
TOWER Trial included relatively few incident fractures (n=
44), with the number of vertebral fractures in study partici-
pants with a DXA BMD test even fewer (n=27). Indeed, the
criterion for low bone mass was the equivalent of a T-score of
−1.67, rather than −2.0 or −2.5, the threshold commonly used
in phase 3 studies. However, this approach represents the
country norm in Japan, and since we examined relationships
across BMD in a continuous fashion, this should not have
affected our results; the higher BMD criterion may have re-
duced our capacity to elucidate relationships between BMD
and efficacy at the very lowest T-scores. Furthermore, al-
though the relationship between metacarpal radiogrammetry
and vertebral fracture risk is uncertain in this population, the
results in the subset who underwent radiogrammetry instead
of DXA appeared similar to those in the whole trial cohort.
Second, the sole outcome of the TOWER study was vertebral
fracture. Thus, it is uncertain whether the same relationship
between efficacy and fracture probability would be observed
with the inclusion of other fracture outcomes, although con-
gruence between vertebral and nonvertebral fracture outcomes
has been documented in other studies [12, 15]. Third, several
FRAX risk variables (parental history of hip fracture, current
smoking, and alcohol intake) were not recorded in the original
TOWER trial. These were set to missing in the current analy-
sis, but, owing to the randomized allocation of patients to
treatment or placebo, this is unlikely to have biased baseline
risk calculations differentially across the two groups. Howev-
er, this may have resulted in an underestimation of fracture
probability overall, and the possibility of a differential effect
across groups remains. Finally, the 10-year probability of a
major osteoporotic fracture rather than hip fracture was used
as the index of fracture risk, since it was found to be more
closely related to the fracture occurrence. However, in a sen-
sitivity analysis using baseline probability for hip fracture,
results were extremely similar.
In conclusion, this analysis has demonstrated, consistent
with previous findings, that treatment with teriparatide once
weekly is associated with a marked decrease in morphometric
vertebral fractures compared to treatment with placebo. How-
ever, in the cohort as a whole, there was no evidence of an
interaction between efficacy and baseline fracture probability.
Although the potential interaction between efficacy and DXA
BMD might support an initiation strategy predicated on strat-
ification by baseline BMD, these findings require replication
in further studies, ideally both of daily and weekly
teriparatide, before they can be confidently incorporated into
any formal policy. Overall, these findings do not provide sup-
port for the stratification of weekly teriparatide prescription
according to baseline fracture risk.
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